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Background: At present, several positron emission tomography (PET) tracers are in use for imaging P-glycoprotein
(P-gp) function in man. At baseline, substrate tracers such as R-[11C]verapamil display low brain concentrations with
a distribution volume of around 1. [11C]phenytoin is supposed to be a weaker P-gp substrate, which may lead to
higher brain concentrations at baseline. This could facilitate assessment of P-gp function when P-gp is upregulated.
The purpose of this study was to synthesize [11C]phenytoin and to characterize its properties as a P-gp tracer.
Methods: [11C]CO was used to synthesize [11C]phenytoin by rhodium-mediated carbonylation. Metabolism and,
using PET, brain pharmacokinetics of [11C]phenytoin were studied in rats. Effects of P-gp function on [11C]phenytoin
uptake were assessed using predosing with tariquidar.
Results: [11C]phenytoin was synthesized via [11C]CO in an overall decay-corrected yield of 22 ± 4%. At 45 min after
administration, 19% and 83% of radioactivity represented intact [11C]phenytoin in the plasma and brain,
respectively. Compared with baseline, tariquidar predosing resulted in a 45% increase in the cerebral distribution
volume of [11C]phenytoin.
Conclusions: Using [11C]CO, the radiosynthesis of [11C]phenytoin could be improved. [11C]phenytoin appeared to
be a rather weak P-gp substrate.
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The blood–brain barrier (BBB) is a tightly connected cell
layer that protects the brain from harmful substances
and regulates transfer of various compounds between
the brain and blood. The tight junctions between endo-
thelial cells of the BBB force drugs to penetrate through
rather than between these cells, either by passive diffu-
sion, active influx or active efflux [1,2]. Active influx and
efflux are processes that can transport molecules against
a concentration gradient, hence requiring ATP-provided
energy. P-glycoprotein (P-gp) is an ATP-dependent 170-
to 180-kDa transmembrane glycoprotein present at the* Correspondence: jverbeek@rnc.vu.nl
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in any medium, provided the original work is pluminal side of the BBB where it prevents its substrates
from entering the brain. This phenomenon may, how-
ever, also be associated with drug-resistance in several
diseases, such as temporal lobe epilepsy [3-5], depression
[6] and HIV [7]. In addition, a change in P-gp function
at the BBB has been proposed as a possible link in the
etiology of several neurological diseases [6-8].
A number of positron emission tomography (PET) tra-
cers [9,10] for imaging P-gp function in man have been
described, and they are all strong substrates of P-gp.
Strong substrate tracers such as [11C]verapamil [11-13],
[11C]desmethyl loperamide [14], [11C]laniquidar [15,16]
and [11C]tariquidar [17] show a relatively low baseline
uptake in both rat and human brain, with a brain-to-
plasma equilibrium concentration ratio, often referred to
as the volume of distribution (VT), of about 1.an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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P-gp substrate. Therefore, in the present study, [11C]
phenytoin was selected as a potential P-gp tracer. As a
weak P-gp substrate and under normal physiological
conditions, [11C]phenytoin is expected to have higher
brain uptake than that of a strong substrate. When P-gp
is upregulated, [11C]phenytoin might be a more sensitive
tracer to detect changes in P-gp function than a strong
substrate tracer. For the latter tracer, the already low sig-
nal will be reduced even further in case of P-gp overex-
pression, and consequently, this change in signal might
be lost in noise. A dosage of 14 mg/kg [11C]phenytoin in
rhesus monkeys resulted in a high brain uptake, which is
consistent with phenytoin being a weak P-gp substrate
[18]. Moreover, phenytoin is a registered drug, which
facilitates easy translation from preclinical use to human
PET applications.
Transition metal-mediated carbonylation using [11C]
CO is a versatile method for the synthesis of compounds
labeled with carbon-11 in the carbonyl position, e.g.,
amides, esters, ketones and carbamates with high spe-
cific activity [19-22]. Previously, it has been shown that
rhodium-mediated reactions with [11C]CO, forming
ureas, are rapid and provide high yield [23-25]. There-
fore, in the present, study [11C]CO was used to
synthesize [11C]phenytoin by rhodium-mediated carbo-
nylation with the aim of improving both specific activity
and radiochemical yield of [11C]phenytoin compared
with an earlier method based on [11C]COCl2 [26], which
resulted in low specific activity of the product following
a rather tedious radiochemistry [26,27]. The purpose of
the present study was to synthesize [11C]phenytoin by
carbonylation and to assess its characteristics as a P-gp
substrate in rats in vivo.
Methods
General
Chemicals were obtained from Sigma Aldrich (St. Louis,
MO, USA) and were used without further purification.
All reactions were carried out under an argon atmos-
phere unless stated otherwise. [11C]CO2 was produced
using an IBA Cyclone 18/9 cyclotron (IBA, Louvain-La-
Neuve, Belgium) by the 14N(p,α)11C nuclear reaction
performed in a 0.5% O2/N2 gas mixture. Water was
purified over a Millipore filter (Millipore, Leiden, The
Netherlands). The silica gel used as stationary phase for
flash column chromatography was grade 9385, 230 to
400 mesh, 60 Å and obtained from Sigma Aldrich.
Chemical shifts (δ) of nuclear magnetic resonance
(NMR) spectra were defined relative to the signal of the
solvent (7.26 for CDCl3 and 2.50 for DMSO-d6) and
measured on a Bruker Avance 250 (Bruker, Billerica,
MA, USA), with δ reported in parts per million relative
to the solvent. Infrared (IR) spectra were obtained usinga Shimadzu FTIR-8400 S (Shimadzu, Kyoto, Japan), and
wavelengths (ν) are reported in per centimeter and (s),
(m) and (w), indicating strong, moderate and weak sig-
nal, respectively. Electrospray ionization high-resolution
mass spectrometry (ESI-HRMS) was carried out using a
Bruker microTOF-Q instrument in positive ion mode
(capillary potential of 4.500 V); electrospray ionization
mass spectrometry was carried out using an AB Sciex
Qtrap 5500 LC-MS/MS instrument (AB Sciex, Foster
City, CA, USA) in negative ion mode. Semi-preparative
high performance liquid chromatography (HPLC) was
performed on an ACE 5-μM C18, 250*10-mm column
(Alltech, Nicholasville, KY, USA) using the following
settings: wavelength 230 nm, eluent MeCN/H2O/TFA
60/40/0.15 (v/v/v) and flow 4 mL·min−1 (method A).
Analytical HPLC was performed on a Kromasil 100 C18
10-μM (4.6 to 250 mm) column (Grace Alltech, Breda,
The Netherlands) with the following settings: wavelength
230 nm, eluent acetonitrile/water/diisopropylamide 75/
25/0.2 (v/v/v) and flow 1 mL·min−1 (method B). Metab-
olite analysis was performed on a Gemini C18 5-μm (10
to 250 mm) column (Phenomenex, Torrance, CA, USA)
(method C) with gradient and a mixture of (A)
acetonitrile and (B) 0.1% trifluoro acetic acid in H2O as
eluent according to the following scheme: 0 min, 90% B
at 0.25 mL·min−1; 0.5 min, 20% B at 4 mL·min−1; 9.0
min, 30% B at 4 mL·min−1; 13 min, 30% B at 4 mL·min−1;
14.0 min, 90% B at 4.0 mL·min−1 and 15 min, 90% B at
0.25 mL·min−1. Tetrahydrofuran (THF), which was used
during experiments, was distilled over LiAlH4 just prior to
the experiments unless stated otherwise.
Synthesis
Synthesis of azido-diphenyl-acetic acid (2)
Sodium azide 1.78 g (27.5 mmol) was dissolved in a
mixture of water (4.5 mL) and CH2Cl2 (7.5 mL). After
cooling the solution in an ice bath, trifluoromethanesul-
fonic anhydride (0.93 mL, 5.6 mmol) was added slowly
for 5 min and then stirred for 2 h at 4°C to form triflyl
azide [23]. The dichloromethane layer was separated,
and the aqueous layer was extracted twice with 4 mL of
CH2Cl2. The combined organic layers were washed with
a saturated aqueous Na2CO3 solution (10 mL). The
resulting solution of triflyl azide in CH2Cl2 was used
without further purification and added to a mixture of
aminodiphenylacetic acid 1 (0.65 g, 2.8 mmol), K2CO3
(0.58 g, 4.2 mmol) and Cu(II)SO4•5H2O (7.0 mg, 28
μmol) in a mixture of H2O (9 mL) and CH3OH (18 mL).
Subsequently, this mixture was stirred overnight at room
temperature. After evaporation of CH2Cl2 and CH3OH
under reduced pressure, the residue was washed twice
with ethyl acetate (10 mL) in a separation funnel. The
water layer was acidified to pH 2 with concentrated HCl
and subsequently extracted four times with CH2Cl2 (10
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and the solvent was evaporated under reduced pressure.
The residual oil was purified by flash column chromatog-
raphy with a mixture of CH2Cl2/CH3OH 97/3 (v/v). The
fractions containing the product were collected, and the
solvent was evaporated under reduced pressure to obtain 2
(0.53 g, 2.1 mmol) as a white solid. Yield 75%, retardation
factor (Rf) of 0.15 (CH2Cl2/CH3OH 97/3 (v/v)).
1H-NMR
(CDCl3) δ: 7.28 to 7.39 (10 H, m, aromatic protons).
13C-
NMR (CDCl3) δ: 128.14, 128.52, 128.88, 138.09. Infrared
spectrum: 2,112 cm−1 (s, N3) and 1,744 cm
−1 (s, C =O).
Synthesis of azidodiphenylacetamide (3)
Azidodiphenylacetic acid 2 (532 mg, 2.1 mmol) was dis-
solved in dry acetonitrile (20 mL) and SOCl2 (5 mL).
The resulting solution was refluxed for 1.5 h to form azi-
dodiphenylacetamide 3. Acetonitrile and SOCl2 were
then removed under reduced pressure, which was fol-
lowed by addition of dry toluene (10 mL) and removal
of residual SOCl2 by co-evaporation under reduced pres-
sure. The co-evaporation procedure with toluene was
then repeated once more. The remaining solid was dis-
solved in dry acetonitrile (20 mL), and ammonia gas was
gently bubbled trough the solution for 30 min; after
which, the flask was closed and the mixture was stirred
overnight at room temperature. After the solvent was
evaporated under reduced pressure, the residue was dis-
solved in CH2Cl2 (30 mL), and this solution was washed
twice with water (20 mL). The CH2Cl2 solution was
dried over Na2SO4 and filtered, and the filtrate was eva-
porated under reduced pressure. The crude product was
purified by flash column chromatography with ethyl
acetate/hexane 45/55 (v/v). The fractions containing the
product were collected, and the solvent was evaporated
under reduced pressure to obtain 402 mg (1.6 mmol) of
3 as a white solid. Yield 76%, Rf 0.20 (ethyl acetate/hex-
ane 45/55 (v/v)) 1H-NMR (CDCl3) δ: 6.09 (1H, s,
CONH2), 6.55 (1H, s, CONH2), 7.39 to 7.52 (10H, m,
aromatic protons). 13C-NMR (CDCl3) 128.33, 128.57,
128.74, 138.75, 172.69. HRMS (ESI) m/z calculated for
C14H12N4O [M
+ Na+] 275.0893 found 275.0903. Elem-
ental analysis calculated: C 66.65, H 4.79, N 22.21;
found: C 66.65, H 4.82, N 22.15. Infrared spectrum:
3,452 cm−1 (m, C =ONH2), 2,110 cm
−1 (s, N3) and 1,682
cm−1 (s, C = ONH2).
Synthesis of [11C]phenytoin
A solution of rhodium(II) acetate dimer (0.35 mg, 0.80
μmol), 1,2-bis(diphenylphosphino)ethane (0.90 mg, 2.2
μmol) and 3 (4.3 mg, 17 μmol) in freshly distilled THF
(400 μL) was prepared in a septum-equipped vial (2.0
mL). The vial was gently heated until there was a color
change from light yellow to dark orange, which indicated
that the desired catalytic complex was formed.The synthesis of [11C]phenytoin was performed using a
semiautomatic synthesis module (Figure 1). The module
was built in-house based on the technology developed for
[11C]CO carbonylation [28]. [11C]CO2 was first trapped
and concentrated on silica gel immersed in liquid nitrogen
(−196°C). Valve V1 was then switched to confine the [11C]
CO2 before heating the trap to room temperature. Next,
the valve was switched again to release the concentrated
[11C]CO2 into a stream of helium (20 mL/min) and over a
gas purification column (silica gel 100/120 mesh (Alltech),
5 mass% water). Subsequently, the [11C]CO2 was reduced
over zinc at 400°C. Formed [11C]CO was trapped on a sil-
ica trap immersed in liquid nitrogen, and unreacted [11C]
CO2 was trapped on an ascarite column (A2).
Valve V2 was switched to position 2 before the CO trap
was heated to ambient temperature. This was followed by
the transfer of [11C]CO to the micro-autoclave in a stream
of helium (3 bar) by switching valve V2 to position 1. After
this transfer, valve V2 was switched back to position 2. The
freshly prepared precursor solution was loaded on the re-
agent loop and transferred to the micro-autoclave using
THF pumped at a pressure of up to 300 bar. This high
pressure forced both [11C]CO and the helium transfer gas
to dissolve in the reagent solution in the micro-autoclave,
which then was heated for 5 min at 120°C to facilitate the
carbonylation reaction. Next, the reaction mixture was
transferred to a vacuumized vial by switching valve V2 to
position 3. The product solution was degassed with helium
(10 mL) to remove residual [11C]CO and other gaseous
compounds. Next, the reaction mixture was diluted with
H2O (1 mL), injected on the preparative HPLC system and
purified using HPLC method A. [11C]phenytoin, with a
retention time in the range of 7 to 9 min, was collected
directly into a vortex evaporator (PET Evap, Scansys Labor-
atortechnik, Copenhagen, Denmark). During fraction col-
lection, the HPLC eluent was evaporated continuously at
60°C under N2 gas at high flow. After the HPLC eluent was
removed, buffered 0.9% NaCl aqueous solution (12 mL, pH
7,4; 8.4-mM Na2HPO4/1.8-mM NaH2PO4) was added, and
the reformulated [11C]phenytoin was passed over a Millex
GV filter (0.22 μM, Millipore, Billerica, MA, USA) and dis-
pensed into a sterile product vial. The chemical and radio-
chemical purity was assessed using analytical HPLC
method B. All radiochemical yields reported are based on
the amount of initial radioactivity at the start of the carbo-
nylation reaction, as determined by measuring the reaction
mixture after transfer from the micro-autoclave. The radio-
active residues remaining in the micro-autoclave after
transfer were negligible.
11C/13C co-labeling of phenytoin
A solution of 3 (10 mg, 40 μmol), rhodium(II) acetate
dimer (0.7 mg, 1.6 μmol) and 1,2-bis(diphenylphosphino)
ethane (DPPE; 1.8 mg, 4.5 μmol) in THF (300 μL)
Figure 1 Schematic overview of the synthesis unit used to synthesize [11C]CO.
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injection loop, which was preloaded with [13C]CO gas.
The content of the loop was transferred to the autoclave
containing [11C]CO as described in the previous section.
The autoclave was heated for 20 min at 120°C. Next, the
reaction mixture was purified using HPLC method A. The
collected fraction was analyzed using HPLC method B to
assess identity and radiochemical and chemical purities.
After decay, acetonitrile was removed from a rotary evap-
orator, after which the water fraction was extracted with
dichloromethane (4 × 10 mL). The combined portions of
dichloromethane were dried over Na2SO4 and filtered. Ro-
tary evaporation yielded 1.3 mg (13% yield) of [13C]pheny-
toin. Analysis with 13C-NMR (DMSO-d6) gave a
spectrum with signals at 156.1, 128.5 and 126.6 ppm.
These signals were also present in the spectrum taken
with isotopically unmodified phenytoin. The signal at
156.1 ppm had the highest intensity and corresponded to
the quaternary carbon of phenytoin. This identity was also
confirmed using an LC/MS/MS system with a negative
ion peak at m/z 252.1.
Animals
Adult male Sprague–Dawley rats (Harlan, Horst, The
Netherlands) weighing 200 to 224 g at arrival were
housed in groups of five to six per cage with unrestricted
access to food (Teklad Global 16% Protein Rodent Diet,Table 1 Overview of [11C]phenytoin scans
Animal Scan 1
1 Baseline
2 Baseline
3 Baseline
4 Tariquidar 15 mg·kg−1
5 Baseline
6 BaselineHarlan, Madison, WI, USA) and water. Rats were kept at
a constant temperature of 21°C and in a 12-h light/dark
cycle in which lights were switched on at 8:00 am. Ani-
mal procedures were performed in accordance with the
Dutch laws on animal experimentation.
Approximately 1 week after habituation, rats were
used in either PET or metabolite studies. Rats were
anesthetized via a nose mask with 4% and 2% isoflurane
in oxygen for induction and maintenance, respectively,
at a rate of 1 L·min−1. The femoral vein and artery were
cannulated 1 to 2 h prior to each study of [11C]pheny-
toin and tariquidar administration, and blood sampling,
respectively. Blood oxygen saturation and body temperature
were monitored throughout surgery and experiments.
Heating and oxygen supply were adjusted to maintain a
body temperature > 36°C and an oxygen saturation > 96%.
Metabolite analysis in the plasma and brain tissue
To study the metabolic profile of [11C]phenytoin in the
plasma and brain, five male Sprague–Dawley rats were
injected with 150 to 250 MBq [11C]phenytoin in the tail
vein under isoflurane anesthesia. Three of these animals
were pretreated with 15 mg·kg−1 tariquidar 20 min prior
to [11C]phenytoin administration. Three arterial blood
samples of 0.5, 0.8 and 1.2 mL were withdrawn at 10, 30
and 45 min or at 5, 15 and 25 min after [11C]phenytoin
injection, respectively. Immediately following the lastScan 2 Scan 3
- -
- -
Tariquidar 15 mg·kg−1 -
Tariquidar 15 mg·kg−1 -
Probenecid 150 mg·kg−1 Tariquidar 15 mg·kg−1
Probenecid 150 mg·kg−1 Tariquidar 15 mg·kg−1
OHO
NH2
OHO
N3
NH2O
N3
ii, iiii
1 2 3
Scheme 1 The synthesis of azidodiphenylacetamide 3. (i) Triflyl azide, K2CO3, Cu(II)SO4·5H2O, CH2Cl2, CH3OH, 16 hr, room temperature (RT),
75% yield. (ii) SOCl2, CH3CN, 90 min, reflux. (iii) NH4, CH3CN, 16 hr, RT, 76% yield.
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was isolated. All blood samples were collected in heparin
tubes and centrifuged at 4.000 rpm for 5 min at 4°C
(Hettich Universal 16, Depex B.V., The Netherlands).
Plasma was separated from blood cells and, between 0.3
and 0.7 mL, was loaded onto a tC-18 Sep-Pak (Waters,
The Netherlands) and washed with 20 mL of water. The
eluate was defined as the polar radiolabeled metabolite
fraction. Thereafter, the tC-18 Sep-Pak was eluted with
1.5 ml of methanol. This eluate was defined as the non-
polar fraction and was analyzed using HPLC method C.
Brain tissue was homogenized with an ultrasonic
homogenizer (Braunsonic 1510, Kronberg, Germany) in
water, under ice cooling, and subsequently centrifuged at
4,000 rpm for 5 min at 4°C. Separated supernatants were
loaded onto a tC-18 Sep-Pak and washed with 20 mL
water to obtain the polar fraction. The nonpolar fraction
was eluted in 1.5 ml of methanol and analyzed with
HPLC method C. The recovery of the metabolite ana-
lysis was validated to be above 95%.
PET studies
Following cannulation of the femoral vein, animals were
positioned in pairs in a double LSO/LYSO layer high-
resolution research tomograph (CTI/Siemens, Knoxville,
TN, USA) [29]. First, for attenuation and scatter correc-
tion purposes, a transmission scan was acquired using a0
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Figure 2 Retention time of [11C]CO2 on silica gel with varying
mass percentages of water. The silica gel was prepared by drying
for 16 h at 120°C, after which water was added.740-MBq two-dimensional fan-collimated 137Cs (662
keV) moving point source [30]. Next, a dynamic emis-
sion scan was acquired immediately following adminis-
tration of 17.1 ± 2.1 MBq (mean ± SD) [11C]phenytoin to
each rat. Two animals had one single [11C]phenytoin
scan; two animals had two consecutive scans, and two
had three consecutive scans. Finally, all animals under-
went an [18F]FDG scan before being euthanized. An
overview of acquired scans is listed in Table 1. Tariqui-
dar, 15 mg·kg−1, was used to completely block P-gp,
while probenecid, 150 mg·kg−1, was used to inhibit
multi-resistant protein (MRP) efflux proteins. Tariquidar
and probenecid were administered i.v. 20 min prior to
the scan start as a 10-min infusion. All animals, except
one, were scanned without any treatment prior to the
first [11C]phenytoin scan. Of the animals that had two
scans, one underwent two post-tariquidar scans (animal
4, Table 1). The aim of this particular set of scans was to
ensure that the order of scans did not affect results. Ani-
mals that underwent three consecutive scans had one
baseline, one post probenecid and one post-tariquidar
scan. During each scan, emission data were acquired for
60 min in list mode and rebinned into the following
frame sequence: 7 × 10, 1 × 20, 3 × 30, 2 × 60, 2 × 150,
2 × 300 and 4 × 600 s. Following corrections for decay,
dead time, attenuation, random and scatter, scans were
reconstructed using a 3D ordinary Poisson ordered sub-
sets expectation maximization algorithm. This resulted
in images with an average spatial resolution of 3 mm full
width half maximum [29]. PET image data were ana-
lyzed using the freely available software package Amide
0.9 [31]. A magnetic resonance (MR)-based rat brain
atlas [32] was used to define five regions of interest
(ROIs): the hippocampus, occipital cortex, parietal cor-
tex, caudate putamen and cerebellum. The MR atlas in-
cluding all ROIs was aligned visually with the summed
[18F]FDG image for each rat. ROIs were then projected
onto all frames of all [11C]phenytoin scans, resulting in
[11C]phenytoin time-activity curves for each scan and
rat.
During each [11C]phenytoin scan, arterial blood sam-
ples of 0.1 mL were taken at 20 and 40 s and at 1, 2, 5,
15, 30 and 60 min after [11C]phenytoin injection. For
animals that underwent three scans, the amount of
Cl
Rh RhCl O
O
Rh
O
O
O
O
Rh
O
O
Figure 3 Rhodium sources used: (Rh(cod)2) and rhodium(II)
acetate dimer.
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ples at 15 and 30 min with a single 20-min sample.
Plasma was obtained by centrifugation at 4,000 rpm for
5 min at 4°C, and activity in both plasma and whole
blood was measured in an automated 1282 Compu-
gamma CS Universal Gamma Counter (LKB Wallac,
Turku, Finland), cross-calibrated against the PET scan-
ner. Standardized uptake values (SUVs) as a function of
time were derived by normalizing measured radioactivity
concentrations against injected dose and body weight.
To obtain a model independent estimate of the brain-
to-plasma partition coefficient, often referred to as vol-
ume of distribution, Logan graphical analysis [33] was
used. Before Logan analysis, both brain and plasma con-
centrations were corrected for labeled metabolites. As
metabolite fractions were not measured at each plasma
or mid-frame time point, linear regression was used to
estimate the fraction of intact [11C]phenytoin at each
time point.
Results and discussion
Synthesis of phenytoin precursor
The synthesis of azidodiphenylacetamide 3, as described
previously by Hohenlohe-Oehringen [34], started from
2-bromo-2,2-diphenylacetonitrile followed by an azida-
tion reaction to yield the crucial intermediate 2-azido-
2,2-diphenylacetonitrile. However, in our hands, this
intermediate could not be synthesized. Attempts to ob-
tain 3 via the corresponding methylester or by first
introducing an amide function were also unsuccessful as
the subsequent conversion to the azide failed. Finally, 3
was synthesized in three reaction steps starting from
aminodiphenylacetic acid 1 and diazo-transfer fromP PP
Figure 4 Phosphine ligands used: triphenylphosphine, DPPE and DPPtriflyl azide [35] to form azidodiphenylacetic acid 2.
Next, the amidation was performed by conversion to 2-
azido-2,2-diphenylacetyl chloride, and subsequent treat-
ment with ammonia gave azidodiphenylacetamide 3 in
an overall yield of 57% after purification by flash column
chromatography, which is shown in Scheme 1.
Production of [11C]CO
[11C]phenytoin was synthesized by carbonylation of 3
using [11C]CO. Although it has been reported that
heated zinc can reduce [11C]CO2 to [
11C]CO, this reac-
tion did not work in our lab [36]. A possible explanation
could be the use of 0.5% oxygen in the target gas, which
is a factor 10 higher than used previously [24,36]. To cir-
cumvent potential deactivation of zinc by rapid oxida-
tion, a column containing silica gel (100/120 mesh) was
implemented to chromatographically purify [11C]CO2.
Retention of [11C]CO2 strongly depended on the mass
percentage of water in the silica gel with less water
resulting in a longer retention time, as depicted in Figure 2.
On the other hand, molecular oxygen has little retention
on silica gel, enabling the removal of O2 by discarding the
effluent prior to the [11C]CO2 fraction.
By testing silica gel with different moisture contents, it
was verified that the reduction proceeded reliably when
[11C]CO2 eluted from the column between 4 to 9 min,
while shorter or longer retention times resulted in per-
manent deactivation of the zinc. The optimum water
content in the silica gel was determined to be 5 mass%
of water. These observations did not support the as-
sumption that O2 was the direct cause of zinc deactiva-
tion. A second possibility could be that the high O2
concentration in the target gas led to formation of nitro-
gen oxides during irradiation [37,38], which in turn
caused the deactivation of zinc [39]. Among all nitrogen
oxides, N2O is the most likely candidate to cause zinc
deactivation based in part on its oxidizing properties. In
addition, it is difficult to remove as it has similar chro-
matographic behavior as CO2 on silica gel, including
peak broadening and increasing retention time with de-
creasing water content in the silica gel, as reported by
Gamo et al. [40]. While the exact reason for the deacti-
vation of zinc needs to be clarified in future studies, the
silica gel column purification facilitated practical use ofPP
P.
NH2O
N3 NH
C11N
H
O
O
i
3 4
Scheme 2 Radiolabeling of [11C]phenytoin 4. (i) [11C]CO, Rh(II)
acetate dimer, DPPE, THF, 5 min, 250 bar, 120°C, 22 ± 4% overall
yield.
Table 2 Yield as function of amount of precursor (3) for
constant amount of rhodium acetate
Precursor 3 Yield
(μmol) (%)
8.4 3
9.1 5
12 7
17 21
21 19
It should be noted that 200 μL out of the 400-μL precursor solution will be
added to the micro-autoclave.
Verbeek et al. EJNMMI Research 2012, 2:36 Page 7 of 11
http://www.ejnmmires.com/content/2/1/36zinc in the [11C]CO synthesis. Typically, the zinc column
needed to be replenished after seven to ten syntheses.
Synthesis of [11C]phenytoin
The synthesis of [11C]phenytoin was performed in a
high-pressure autoclave according to the general method
developed by Kihlberg et al. [28]. Use of the high-
pressure method provided an efficient way of transfer-
ring the minute amount of [11C]CO into the reaction
solution and to circumvent low incorporation yields
associated with poor solubility of [11C]CO.
Several rhodium catalyst complexes were explored
during optimization of the [11C]phenytoin synthesis. The
commercially available Wilkinson’s catalyst gave [11C]
phenytoin in low yields, up to 4%, and generally poor
conversion of [11C]CO to nonvolatile products. Next,
the catalytic activity of complexes formed from chloro
(1,5-cyclooctadiene)rhodium(I) dimer (Rh(cod)2) andTable 3 Effect of rhodium acetate, DPPE and their ratio
on yield
Entry Rhodium acetate DPPE Ratio Yield
(μmol) (μmol) DPPE/rhodium (%)
1 2.8 1.3 0.5 2
2 2.2 1.5 0.7 3
3 6.2 5.5 0.9 1
4 2.0 1.8 0.9 7
5 1.4 1.5 1.1 9
6 2.4 2.6 1.1 9
7 1.8 2.0 1.1 18
8 1.4 1.7 1.2 27
9 1.4 1.7 1.2 24
10 1.6 2.0 1.3 25
11 4.2 4.4 1.3 12
12 0.6 0.9 1.5 4
13 1.4 2.3 1.6 21
14 2.4 6.2 2.6 3
It should be noted that 200 μL out of the 400-μL precursor solution will be
added to the micro-autoclave.with rhodium(II) acetate dimer, which are depicted in
Figure 3, was explored.
These rhodium sources were utilized in combination
with three different phosphine ligands (Figure 4): triphe-
nylphosphine, 1,2-bis(diphenylphosphino)ethane and 1,3-
bis(diphenylphosphino)propane (DPPP). DPPE gave the
best results of these three phosphines when combined
with Rh(cod)2, with yields up to 22% and an average radio-
chemical yield of 11 ± 10%, but with poor reproducibility.
Both DPPP and triphenylphosphine gave lower yields.
Next, rhodium(II) acetate dimer was investigated, and
again, DPPE gave better results than DPPP and triphe-
nylphosphine. In addition, yields proved to be more re-
producible compared with Rh(cod)2. Preheating the
reaction mixture improved both yield and reproducibil-
ity. The optimal amount of precursor 3 seemed to be
around 17 μmol. A decrease in this amount led to a de-
crease in yield, while an increase did not improve the
yield (Table 2).
By varying the ratio of rhodium acetate dimer to
DPPE, the optimum was found to be between 1.2 and
1.6 (Table 3). In addition, the effect of catalyst load was
investigated. The optimum was obtained for 0.7 to 0.9
μmol rhodium acetate dimer and 1.7 to 2.3 μmol DPPE.
A reaction time of 5 min was deemed sufficient as
longer times did not increase the yield. The reaction per-
formed best at 120°C. No improvement was seen for
higher temperatures, and the yield dropped to 4% at 80°CTable 4 Percentage of intact [11C]phenytoin at different
time points after injection (N = 2)
Time (min) Plasma (%) Brain (%)
5 60 ± 7
10 50 ± 16
15 38 ± 3
25 28 ± 2 95 ± 1
30 32 ± 18
45 19 ± 8 83 ± 5
Although moderate [11C]phenytoin metabolism in the periphery may be
acceptable, it requires metabolite correction of plasma input functions for
quantification of tracer kinetics, especially since it will be difficult to define a
proper reference region.
Figure 5 Typical preparative HPLC chromatogram with UV absorption (upper panel) and radioactivity (lower panel) signals.
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http://www.ejnmmires.com/content/2/1/36and to 9% at 100°C. Dimethylformamide was also
attempted as a solvent but gave no yield.
After these optimization steps, rhodium acetate dimer
in combination with DPPE gave reliable yields of 19% to
27%, as illustrated in Scheme 2. The (optimal) reaction
conditions used were 16 to 18 μmol 3, 0.7 to 0.9 μmol
rhodium acetate dimer and 1.7 to 2.3 μmol DPPE, in
400 μmol THF at 120°C for 5 min under a pressure of
250 bar for 5 min to yield 22 ± 4% decay-corrected (1 to 2
GBq) [11C]phenytoin with a specific activity of 277 ± 67
GBq μmol−1 at end of synthesis (EOS). It should be noted
that via the loop, in practice, 200 μL out of the 400-μL
precursor solution was added to the micro-autoclave.
Purification of [11C]phenytoin was performed by pre-
parative HPLC using method A. The retention times of
[11C]phenytoin and precursor 3 were approximately 8
and 18 min, respectively, as shown in Figure 5.
The standard method for removing the HPLC eluent
is solid-phase extraction with commercially available
cartridges. Several cartridges were tested: the Waters
C18 plus, tC-18, C-18 light and C8, the ion exchange
columns PS-OH and PS-HCO3 from Machery-NagelFigure 6 Summed (10 to 60 min) images of [11C]phenytoin in the rat
intravenous administration of tariquidar (15 mg·kg−1) in the rat. The brain i
shown on an MR template image (left); the overlay image is shown on the(Düren, Germany), the Alltech SAX and the OASIS HLB
(Waters Corp., Milford, MA, USA). Except for the PS-
HCO3, however, all these cartridges suffered from either
poor trapping, poor recovery or low reproducibility. Al-
though the PS-HCO3 cartridge showed good trapping
and good elution with acidic ethanol, an impurity, how-
ever, co-eluted with [11C]phenytoin, making this cart-
ridge unsuitable for radiopharmaceutical production. As
solid-phase extraction proved to be troublesome, the
HPLC solvent was removed by means of a vortex evap-
orator (PET Evap, Scansys Laboratortechnik). The HPLC
fraction containing [11C]phenytoin was transferred into
the PET Evap, which was heated to 60°C. Evaporation
was facilitated by a high flow of N2 gas. When collection
of HPLC fractions was complete, the transfer line to the
PET Evap was rinsed with 5 mL of water to recover the
remaining [11C]phenytoin. Two minutes after the HPLC
fraction was collected, evaporation was complete. Heat-
ing of the PET Evap was switched off; the N2 flow was
reduced, and the product was washed out of the PET
Evap with 10 mL PBS buffer in saline. After passing over
a sterile filter (Millex GV, Millipore), the final productbrain. Before (second image) and 15 min after (third image)
s outlined in both images. Regions of interest used in the analysis are
right.
00.5
1
1.5
0 10 20 30 40 50 60
Time (min)
SU
V
Hippocampus - Hippocampus +
Cerebellum - Cerebellum +
Figure 7 [11C]phenytoin time-activity curves in selected rat
brain regions. Baseline (open symbols) and after administration of
tariquidar (closed symbols). The injected dose was 17.1 ± 2.1 MBq.
Error bars represent standard deviation.
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http://www.ejnmmires.com/content/2/1/36ready for injection was obtained in a yield of 22 ± 4%,
decay-corrected (1 to 2 GBq), and a specific activity of
277 ± 67 GBq·μmol−1 at EOS with a total synthesis time
of approximately 35 min. The radiochemical purity was
≥98%, and no visible UV peaks were observed in the
analytical HPLC chromatogram.
The identity of [11C]phenytoin was further confirmed
by co-synthesis of phenytoin with both [13C]CO and
[11C]CO. Carbon NMR showed a high signal at 156.1
ppm, which corresponds to the carbonyl peak in the
reference phenytoin. Next, the identity of [13C]phenytoin
was also confirmed with mass spectrometry which, as
expected, showed a negative ion peak at m/z 252.1. In
addition, analytical HPLC confirmed that [11C]phenytoin
was formed.Metabolite analysis
Metabolism of [11C]phenytoin in the plasma was rela-
tively fast. Forty-five minutes after administration, 19%
of radioactivity in the blood was still intact [11C]pheny-
toin. Metabolism appeared to be slower in the brain, or
some metabolites might originate from the plasma with
83% intact [11C]phenytoin at 45 min, as shown in
Table 4. The two radioactive nonpolar metabolites
observed in the plasma were not detected in the brain.
In addition, there was no difference in metabolism be-
tween tariquidar-treated and untreated rats.Table 5 Results of Logan analysis using metabolite-corrected
Hippocampus Occipital cortex
Baseline (n = 5) (VT) 0.96 ± 0.09 0.91 ± 0.06
Tariquidar
(n = 5) (VT) 1.43 ± 0.07 1.30 ± 0.11
Probenecid
(n = 2) (VT) 0.59 ± 0.00 0.59 ± 0.00PET imaging
Typical summed [11C]phenytoin images (10 to 60 min)
before and after tariquidar administration are shown in
Figure 6. Cerebral uptake of [11C]phenytoin at baseline
was low and rather homogenous throughout the brain.
Time-activity curves, expressed in SUV, are shown in
Figure 7. [11C]phenytoin displayed fast initial uptake fol-
lowed by fairly fast clearance from the brain. After tari-
quidar administration, the brain SUV of [11C]phenytoin
at 10 to 60 min increased on average by about 50%. The
maximum SUV was around 0.8 and 0.9 for baseline and
post-tariquidar scans, respectively. At 60 min, these
values (corrected for metabolites) reduced to around 0.2
and 0.3 for baseline and post-tariquidar scans, respect-
ively. More avid P-gp substrates, such as [11C]verapamil,
have a brain SUV that is about half of these values at
baseline [41].
Logan analysis showed that VT, i.e., the brain-to-
plasma concentration ratio, of [11C]phenytoin increased
by about 45% after administration of 15 mg·kg−1 tariqui-
dar (Table 5), a dose that completely inhibits P-gp. The
same dose resulted in a much larger increase in VT (in
the order of 1000%) for the established P-gp tracer (R)-
[11C]verapamil [42], indicating that [11C]phenytoin has a
rather moderate affinity for P-gp.
The animals treated with probenecid experienced a se-
verely depressed breathing frequency during 30 to 40
min after the probenecid administration, and this obser-
vation, i.e., discomfort to the animals, was the reason for
not increasing the number of animals that were treated
with probenecid. It is difficult to draw any conclusion
from the studies with probenecid as the animals were in
such poor conditions. Nevertheless, there was no indica-
tion of an increase in VT, which would have supported
an interaction between [11C]phenytoin and MRP.
Initial [11C]phenytoin plasma concentrations after tari-
quidar treatment were somewhat lower than at baseline,
but towards the end of the scans, plasma concentrations
were similar. The initial decrease in plasma concentra-
tion after tariquidar administration is probably due to
increased uptake of [11C]phenytoin in other tissues
where P-gp is also inhibited.
Taken together, these initial preclinical studies showed
that [11C]phenytoin has good tracer properties, i.e., mod-
erate metabolic stability in the brain and favorableplasma input and metabolite-corrected brain data
Parietal cortex Caudate putamen Cerebellum
0.91 ± 0.08 0.98 ± 0.08 1.02 ± 0.08
1.35 ± 0.11 1.48 ± 0.12 1.48 ± 0.09
0.57 ± 0.03 0.57 ± 0.01 0.61 ± 0.01
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approximately 5 min after bolus injection in rats. In line
with the initial hypothesis, [11C]phenytoin showed a
higher baseline signal than more established tracers. Tar-
iquidar predosing studies confirmed that [11C]phenytoin
is indeed a weak P-gp substrate. It remains to be demon-
strated, however, whether [11C]phenytoin will be a useful
tracer to detect changes in P-gp expression and/or func-
tionality. This can be studied in experimental animal
models subjected to chemoconvulsants or electrical
stimulation thereby inducing an epileptogenic process,
which ultimately results in spontaneous epilepsy and
pharmacoresistance [3,5,10]. Altered P-gp expression
and functionality have been demonstrated in these mod-
els, and using [11C]phenytoin, this might be reflected in
decreased uptake at baseline, altered response and/or
tariquidar treatment or altered brain pharmacokinetics.
It might even be easier to demonstrate in the (larger)
human brain of pharmacoresistant epilepsy patients as
altered P-gp functionality is likely to be local, allowing
for a comparison of affected and unaffected cerebral
regions.Conclusions
The radiosynthesis of [11C]phenytoin was improved by
using [11C]CO rather than [11C]phosgene. [11C]pheny-
toin showed slow metabolism in the brain area in vivo
but appeared to be a moderate P-gp substrate in rats.
Compared with other P-gp substrate tracers, [11C]pheny-
toin displayed a higher baseline signal and a less pro-
nounced increase after P-gp inhibition.
Abbreviations
BBB: blood–brain barrier; DPPE: 1,2-bis(diphenylphosphino)ethane; DPPP: 1,3-
bis(diphenylphosphino)propane; P-gp: P-glycoprotein; MRP: multi-resistant
protein; PET: positron emission tomography; Rh(cod)2: Chloro(1,5-
cyclooctadiene)rhodium(I) dimer; SUV: standardized uptake value;
THF: tetrahydrofuran; VT: volume of distribution.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
Each author contributed significantly to the submitted work, and all authors
assisted in drafting the manuscript. JV, JE and ADW were in charge of the
study, synthesis, radiosynthesis as well as acquiring, analyzing and
interpreting the data. SS and ML were in charge of the animal study and
analysis of the animal PET data. MPJM assisted with the radiosynthesis. MR
was in charge of the metabolite analysis. ECML, RAV and AAL, with expertise
in epilepsy research and preclinical study design and PET, contributed to the
design of the study, analysis and interpretation of data. All authors read and
approved the final manuscript.
Acknowledgements
This work was funded by the EU 7th framework programme EURIPIDES,
grant no. HEALTH-F5-2007-201380. The authors like to acknowledge AJ Poot,
RC Schuit, I de Greeuw, M Verlaan and M Schenke for their assistance during
the experiments, and the BV Cyclotron VU for providing the [11C]CO2.Author details
1Department of Nuclear Medicine & PET Research, Radionuclide Centre, VU
University Medical Center, P.O. box 7057, Amsterdam 1081, HV, The
Netherlands. 2Division of Pharmacology, LACDR, Leiden University, Leiden
2300, RA, The Netherlands. 3Epilepsy Institutes of The Netherlands
Foundation (SEIN), Heemstede 2103, SW, The Netherlands.
Received: 11 April 2012 Accepted: 9 June 2012
Published: 2 July 2012
References
1. Cordon-Cardo C, O’Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed
MR, Bertino JR: Multidrug-resistance gene (P-glycoprotein) is expressed
by endothelial cells at blood–brain barrier sites. Proc Natl Acad Sci U S A
1989, 86:695–698.
2. Pike VW: PET radiotracers: crossing the blood–brain barrier and surviving
metabolism. Trends Pharmacol Sci 2009, 30(8):431–440.
3. Löscher W, Sills GJ: Drug resistance in epilepsy: why is a simple
explanation not enough? Epilepsia 2007, 48:2369–2378.
4. Luna-Tortos C, Fedrowitz M, Löscher W: Several major antiepileptic drugs
are substrates for human P-glycoprotein. Neuropharmacology 2008,
55:1364–1375.
5. Löscher W, Potschka H: Role of multidrug transporters in
pharmacoresistance to antiepileptic drugs. J Pharmacol Exp Ther 2002,
301:7–14.
6. Szabo D, Szabo G, Ocsovszki O, Aszalos A, Molnar J: Anti-psychotic drugs
reverse multidrug resistance of tumor cell lines and human AML cells ex-
vivo. Cancer Lett 1999, 139:115–119.
7. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, Wilkinson GR:
The drug transporter P-glycoprotein limits oral absorption and brain
entry of HIV-1 protease inhibitors. J Clin Invest 1998,
101:289–294.
8. van Assema D, Lubberink M, Bauer M, van der Flier WM, Schuit RC,
Windhorst AD, Comans EFI, Hoetjes NJ, Tolboom N, Langer O, Müller M,
Scheltens P, Lammertsma AA, van Berckel BNM: Brain blood–brain barrier
P-glycoprotein function in Alzheimer’s disease. Brain 2012,
135:181–189.
9. Luurtsema G, Verbeek J, Lubberink M, Lammertsma AA, Dierckx R, Elsinga P,
Windhorst AD, van Waarde A: Carbon-11 labeled tracers for in vivo
imaging P-glycoprotein function: kinetics, advantages and
disadvantages. Curr Top Med Chem 2010, 10(17):1820–1833.
10. Syvänen S, Hammarlund-Udenaes M: Using PET studies of P-gp function
to elucidate mechanisms underlying the disposition of drugs. Curr Top
Med Chem 2010, 10(17):1799–1809.
11. Bart J, Willemsen AT, Groen HJ, van der Graaf WT, Wegman TD, Vaalburg W,
de Vries EG, Hendrikse NH: Quantitative assessment of P-glycoprotein
function in the rat blood–brain barrier by distribution volume of [11C]
verapamil measured with PET. NeuroImage 2003, 20(3):1775–1782.
12. Syvänen S, Blomquist G, Sprycha M, Höglund AU, Roman M, Eriksson O,
Hammarlund-Udenaes M, Långström B, Bergström M: Duration and degree
of cyclosporin induced P-glycoprotein inhibition in the rat blood–brain
barrier can be studied with PET. NeuroImage 2006, 32(3):1134–1141.
13. Sasongko L, Link JM, Muzi M, Mankoff DA, Yang X, Collier AC, Shoner SC,
Unadkat JD: Imaging P-glycoprotein transport activity at the human
blood–brain barrier with positron emission tomography. Clin Pharmacol
Ther 2005, 77(6):503–514.
14. Zoghbi SS, Liow JS, Lazarova N, Hong J, Tuan E, Gladding RL, Innis RB, Pike
VW: [11C]N-Desmethyl-loperamide is an improved radiotracer for studying
brain P-gp function. NeuroImage 2008, 41:T106.
15. Luurtsema G, Schuit RC, Klok RP, Verbeek J, Leysen JE, Lammertsma AA,
Windhorst AD: Evaluation of [11C]laniquidar as a tracer of P-glycoprotein:
radiosynthesis and biodistribution in rats. Nucl Med Biol 2009,
36:643–649.
16. Moerman L, Dumolyn C, Boon P, De Vos F: The influence of mass of [11C]
laniquidar and [11C]-N-desmethyl-loperamide on P-glycoprotein
blockage at the blood–brain barrier. Nucl Med Biol 2012, 39:121–125.
17. Bauer F, Kuntner C, Bankstahl J, Wanek T, Bankstahl M, Stanek J, Mairinger S,
Dörner B, Löscher W, Muller M, Erker T, Langer O: Synthesis and in vivo
evaluation of [11C]tariquidar, a positron emission tomography
radiotracer based on a third-generation P-glycoprotein inhibitor.
Bioorgan Med Chem 2010, 18:5489–5497.
Verbeek et al. EJNMMI Research 2012, 2:36 Page 11 of 11
http://www.ejnmmires.com/content/2/1/3618. Stavchansky SA, Tilbury RS, McDonald JM, Kostenbauer HB: In vivo
distribution of carbon-11 phenytoin and its major metabolite, and their
use in scintigraphic imaging. J Nucl Med 1978, 19:936–941.
19. Kihlberg T, Lǻngstrom B: Biologically active 11C-labelled amides using
palladium-mediated reactions with aryl halides and [11C]carbon
monoxide. J Org Chem 1999, 64(25):9201–9205.
20. Kihlberg T, Karimi F, Lǻngstrom B: [11C]carbon monoxide in selenium-
mediated synthesis of 11C-carbamyol compounds. J Org Chem 2002,
67(11):3687–3692.
21. Eriksson J, Åberg O, Lǻngstrom B: Synthesis of [C-11]/[C-13]acrylamides by
palladium-mediated carbonylation. Eur J Org Chem 2007,
3:455–461.
22. Langstrom B, Itsenko O, Rahman O: [C-11]Carbon monoxide, a versatile
and useful precursor in labelling chemistry for PET ligand development.
J Labelled Compd Rad 2007, 50:794–810.
23. Doi H, Barletta J, Suzuki M, Noyori R, Watanabe Y, Lǻngstrom B: Synthesis of
11C-labelled N, N0-diphenylurea and ethyl phenylcarbamate by a
rhodium-promoted carbonylation via [11C]isocyanatobenzene using
phenyl azide and [11C]carbon monoxide. Org Biomol Chem 2004,
2(21):3063–3066.
24. Barletta J, Karimi F, Lǻngstrom B: Synthesis of [11C-carbonyl]hydroxyureas
by a rhodium-mediated carbonylation reaction using [11C]carbon
monoxide. J Labelled Compd Rad 2006, 49(5):429–436.
25. Åberg O, Langstrom B: Synthesis of substituted [11C]ureas and [11C]
sulphonylureas by Rh(I)-mediated carbonylation. J Labelled Compd Rad
2011, 54(1):38–42.
26. Roeda D, Westera G: The synthesis of some 11C-labelled antiepileptic
drugs with potential utility as radiopharmaceuticals: hydantoins and
barbiturates. Appl Radiat Isotopes 1981, 32:843–845.
27. Roeda D, Kuhnast B, Hammadi A, Dolle F: The service hospitalier Frédéric
Joliot – contributions to PET chemistry over the years. J Labelled Compd
Rad 2007, 50:848–866.
28. Kihlberg T, Långström B, Ferm T, Eriksson J: Methods and apparatus for
production and use of [11C] carbon monoxide in labelling synthesis, WIPO.;
2006. Patent WO/2006/008603.
29. de Jong HW, van Velden FH, Kloet RW, Buijs FL, Boellaard R, Lammertsma
AA: Performance evaluation of the ECAT HRRT: an LSO-LYSO double
layer high resolution, high sensitivity scanner. Phys Med Biol 2007,
52:1505–1526.
30. van Velden FH, Kloet RW, van Berckel BN, Lammertsma AA, Boellaard R:
Accuracy of 3-dimensional reconstruction algorithms for the high-
resolution research tomograph. J Nucl Med 2009, 50:72–80.
31. Loening AM, Gambhir SS: AMIDE: a free software tool for multimodality
medical image analysis. Mol Imaging 2003, 2:131–137.
32. Buiter HJ, Leysen JE, Fisher A, Huisman MC, Knol DL, Lammertsma AA,
Windhorst AD: [11C]AF150(S), an agonist PET ligand for in vivo imaging of
the M1 muscarinic acetylcholine receptor. J Labelled Compd Rad 2009,
52:S239–S239.
33. Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, MacGregor
RR: Graphical analysis of reversible radioligand binding from time-
activity measurements applied to [N-11C-methyl]-(−)-cocaine PET studies
in human subjects. J Cereb Blood Flow Metab 1990, 10(5):740–747.
34. Hohenlohe-Oehringen K: Hydrierende Cyclisierung von Azidoverbindungen.
Monatsh Chem 1958, 89:562–569.
35. Lundquist JT, Pelletier JC: Improved solid-phase peptide synthesis method
utilizing a-Azide-protected amino acids. Org Lett 2002, 3(5):781–783.
36. Welch MJ, Ter-Pogossian MM: Preparation of short half-lived radioactive
gases for medical studies. Radiat Res 1968, 36(3):580–587.
37. Kasyutich VL, McMahon A, Barnhart T, Martin PA: On-line monitoring of
cyclotron target-gas output by means of tunable salt diode laser
absorption spectroscopy. Appl phys B-Lasers O 2008,
93(2):701–711.
38. van der Linde SC, Jansen WPA, de Goeij JJM, van IJzeldoorn LJ, Kapteijn F:
In-target production of high specific radioactivity [15O]nitrous oxide by
deuteron irradiation of nitrogen gas. Appl Radiat Isotopes 2000, 52(1):77–85.
39. Clark JC, Buckingham PD: Short-lived Radioactive Gases for Clinical use.
Oxford: Butterworth-Heinemann; 1975:227–237.
40. Gamo T, Horibe Y: Gas chromatographic separation of CO2 and N2O for
measurement of δ13C in atmospheric CO2. Geochem J 1985, 19(3):171–174.
41. Syvänen S, Lindhe O, Palner M, Kornum BR, Rahman O, Långström B,
Knudsen GM, Hammarlund-Udenaes M: Species differences in blood–brainbarrier transport of three positron emission tomography radioligands
with emphasis on P-glycoprotein transport. Drug Metab Dispos 2009,
37:635–643.
42. Syvänen S, Luurtsema G, Molthoff CFM, Windhorst AD, Voskuyl RA, de
Lange ECM: (R)-[11C]Verapamil PET studies to assess changes in P-
glycoprotein expression and functionality in rat blood–brain barrier after
exposure to kainate-induced status epilepticus. BMC Medical Imaging
2011, 11:1.
doi:10.1186/2191-219X-2-36
Cite this article as: Verbeek et al.: [11C]phenytoin revisited: synthesis by
[11C]CO carbonylation and first evaluation as a P-gp tracer in rats.
EJNMMI Research 2012 2:36.Submit your manuscript to a 
journal and beneﬁ t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
